- Home
- MSB vs TSHA Comparison
MSB vs TSHA Comparison
Compare MSB & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- TSHA
- Stock Information
- Founded
- MSB 1961
- TSHA 2019
- Country
- MSB United States
- TSHA United States
- Employees
- MSB N/A
- TSHA N/A
- Industry
- MSB Metal Mining
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- MSB Basic Materials
- TSHA Health Care
- Exchange
- MSB Nasdaq
- TSHA Nasdaq
- Market Cap
- MSB 354.1M
- TSHA 403.7M
- IPO Year
- MSB N/A
- TSHA 2020
- Fundamental
- Price
- MSB $28.16
- TSHA $1.88
- Analyst Decision
- MSB
- TSHA Strong Buy
- Analyst Count
- MSB 0
- TSHA 8
- Target Price
- MSB N/A
- TSHA $6.63
- AVG Volume (30 Days)
- MSB 24.6K
- TSHA 3.7M
- Earning Date
- MSB 01-01-0001
- TSHA 11-13-2024
- Dividend Yield
- MSB 5.49%
- TSHA N/A
- EPS Growth
- MSB 714.88
- TSHA N/A
- EPS
- MSB 7.00
- TSHA N/A
- Revenue
- MSB $26,785,162.00
- TSHA $9,915,000.00
- Revenue This Year
- MSB N/A
- TSHA N/A
- Revenue Next Year
- MSB N/A
- TSHA N/A
- P/E Ratio
- MSB $4.05
- TSHA N/A
- Revenue Growth
- MSB 85.21
- TSHA N/A
- 52 Week Low
- MSB $15.93
- TSHA $1.19
- 52 Week High
- MSB $29.72
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- MSB 55.99
- TSHA 40.22
- Support Level
- MSB $27.04
- TSHA $1.75
- Resistance Level
- MSB $28.89
- TSHA $2.72
- Average True Range (ATR)
- MSB 1.13
- TSHA 0.17
- MACD
- MSB 0.02
- TSHA -0.06
- Stochastic Oscillator
- MSB 65.14
- TSHA 13.47
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of the assets held. The company's principally wholly-owned segment is the iron ore mining segment and it generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.